source
- Biogen’s early Phase 2 data supports tau-targeting Alzheimer’s approachBiogen has released early Phase 2 results for its experimental Alzheimer’s therapy diranersen, indicating that reducing tau protein levels may lead to cognitive benefits. The findings add to a lon…
- Argon Medical issues correction for convenience kits containing lidocaine ampules after FDA safety alertArgon Medical has sent a correction notice to customers about certain convenience kits that include lidocaine HCl ampules supplied by Spectra Medical Devices. The FDA has classified this correctio…